<b>Conclusions:</b> Our study demonstrated that the ARGs could serve as a novel biomarker for predicting the prognosis of patients with HER2-positive breast cancer and providing new insights into immunotherapy strategies for these patients. Here, ERBB2 is linked to breast carcinoma.